Investigating the dynamic interactions between CAR-T cells and the tumor microenvironment: intelligent regulation strategies
Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated significant success in treating hematological malignancies; however, its effectiveness is often constrained by the immunosuppressive network within the tumor microenvironment (TME). The interactions between CAR-T cells and the TME are complex and variable, and the regulatory mechanisms underlying these interactions are reviewed here. This review highlights the effect of TME heterogeneity on therapeutic outcomes and offers a comprehensive framework for understanding the dynamic evolution of the TME at high resolution by integrating insights from single-cell multi-omics and spatial omics technologies. This review also focuses on intervention strategies, including nanotechnology-based delivery systems, metabolic reprogramming, and genetic engineering, that enable active modulation of the TME. A conceptual shift from passive resistance to programmable regulation is proposed, in which CAR-T cells and their carriers are engineered to sense cues from the TME and respond through conditional, intelligent regulatory circuits that remodel the TME. This review combines mechanistic insights with translational strategies, offering a cohesive perspective on overcoming resistance and improving the efficacy, safety, and durability of CAR-T therapies. These advancements are expected to accelerate the development of precision immunotherapy for malignant tumors.
Related
- Adaptive Intelligent Microneedles for Sustained Wound Healing: Translating Microenvironment Signals into Stage-Specific Therapeutic Responses
- Intelligent UPQC control using SA-GANN and optimized DC-link regulation in grid-connected microgrids
- NETs and the thrombo-immune microenvironment: immune heterogeneity in recanalization, reperfusion, hemorrhagic transformation, and antithrombotic strategies
- Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib
- Strategies of mechanical adaptations of circulating tumor cells and properties of their cellular microenvironment have predictive and prognostic biomarker value
BibTeX
@article{zhu2026investigating,
title = {{Investigating the dynamic interactions between CAR-T cells and the tumor microenvironment: intelligent regulation strategies}},
author = {Xiuxian Zhu and Ibrahim Ahmed Saleh Murshed and Ying Li and Yuhong Yin and Yu Han and Zhegong Hu and Xiaoyan Wu},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.2010859},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.2010859},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Investigating the dynamic interactions between CAR-T cells and the tumor microenvironment: intelligent regulation strategies
AU - Xiuxian Zhu
AU - Ibrahim Ahmed Saleh Murshed
AU - Ying Li
AU - Yuhong Yin
AU - Yu Han
AU - Zhegong Hu
AU - Xiaoyan Wu
PY - 2026
DA - 2026/11/03
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.2010859
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.2010859
AB - Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated significant success in treating hematological malignancies; however, its effectiveness is often constrained by the immunosuppressive network within the tumor microenvironment (TME). The interactions between CAR-T cells and the TME are complex and variable, and the regulatory mechanisms underlying these interactions are reviewed here. This review highlights the effect of TME heterogeneity on therapeutic outcomes and offers a comprehensive framework for understanding the dynamic evolution of the TME at high resolution by integrating insights from single-cell multi-omics and spatial omics technologies. This review also focuses on intervention strategies, including nanotechnology-based delivery systems, metabolic reprogramming, and genetic engineering, that enable active modulation of the TME. A conceptual shift from passive resistance to programmable regulation is proposed, in which CAR-T cells and their carriers are engineered to sense cues from the TME and respond through conditional, intelligent regulatory circuits that remodel the TME. This review combines mechanistic insights with translational strategies, offering a cohesive perspective on overcoming resistance and improving the efficacy, safety, and durability of CAR-T therapies. These advancements are expected to accelerate the development of precision immunotherapy for malignant tumors.
SN - 2234-943X
ER -